Barinthus Biotherapeutics named as Life Sciences and Health Tech company of the year
Barinthus Biotherapeutics, based at Harwell Campus, has been named as Life Sciences and Health Tech company of the year, by The Business Magazine’s Tech and Innovation Awards 2024.
The sixth annual Thames Valley Tech & Innovation Awards showcased the outstanding achievements of a diverse range of leading businesses from across the region, with Barinthus Biotherapeutics securing the award for demonstrating sustained innovation and commercial success for several years.
“Our work is based around what we can do for patients and guiding them to a cure for diseases, in particular hepatitis B and coeliac disease. We are growing by working in partnership with institutions in these areas as well as other projects, for example, on treating shingles. Any biotech company will tell you the huge challenge is to balance doing good for patients with meeting your business development objectives. For us, it’s about trying to focus on where we can do the most good with the resources that we have.” Jonathan Blackbourn, Investor Relations and Public Relations Manager, Barinthus Biotherapeutics
Freeths, which sponsored the award specifically noted that ‘to support the development of its programs, Barinthus had established partnerships with leading institutions worldwide. With a powerful suite of innovative technologies. Barinthus aims to create more effective immunotherapies for the treatment of infectious diseases, cancer, and autoimmunity.’
Richard Thompson, Managing Director of The Business Magazine, said: “We had many, many excellent entries, and I’d like to thank the judges – who interviewed a number of the shortlisted companies and diligently assessed the strengths and potential of the contenders.
Alongside Barinthus Biotherapeutics, ARC member OMass Therapeutics based at ARC Oxford was also shortlisted for the category.
Barinthus Biotherapeutics is a key part of Harwell’s Health tech cluster, mase up of nearly 80 organisations. From medtech and biopharma, to medical imaging and cell and gene therapy across the cluster, the companies at Harwell are answering the fundamental questions impacting human health today.
Stay up to date the latest Harwell news on our social platforms.
